Cost-effectiveness analysis of germline brca mutation testing and olaparib treatment in metastatic breast cancer: An evaluation of codependent technologies
File version
Author(s)
Scuffham, P
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Copenhagen, Denmark
License
Abstract
Genetic testing for a germline BRCA mutation in women with HER2-negative metastatic breast cancer (MBC) can guide targeted treatment with PARP inhibitors (e.g. olaparib) and inform cancer prevention strategies (e.g., risk-reducing surgery) for family members of women who test positive. Unlike BRCA testing in localised breast cancer, the cost-effectiveness of genetic testing in MBC is unknown. This study aimed to evaluate the cost-effectiveness of BRCA testing in women with MBC to guide olaparib treatment.
Journal Title
Conference Title
VALUE IN HEALTH
Book Title
Edition
Volume
22
Issue
Supplement 3
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
NHMRC
Grant identifier(s)
APP1121232
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Applied economics
Social Sciences
Science & Technology
Life Sciences & Biomedicine
Economics
Health Care Sciences & Services
Persistent link to this record
Citation
Tuffaha, H; Scuffham, P, Cost-effectiveness analysis of germline brca mutation testing and olaparib treatment in metastatic breast cancer: An evaluation of codependent technologies, Value in Health, 2019, 22, pp. S454-S454